Scholarlink

<p>Methylphenidate is a first-line treatment for attention-deficit/hyperactivity disorder (ADHD). In experimental settings, placebo-controlled titration (PCT) of methylphenidate has shown benefits, including the identification of placebo responders and greater symptom improvement. However, the use of PCT in clinical practice remains limited. Implementing PCT may help reduce overprescription of methylphenidate and inform clinical guidelines for the pharmacological management of children with ADHD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adis Summary of Research: Improving methylphenidate titration in children with attention-deficit/hyperactivity disorder (ADHD): a randomized controlled trial using placebo-controlled titration implemented in clinical practice

  • 期刊论文

  • 发表日期：

    2025年10月15日

查看全文
  • Hannah A. Blair

摘要

Methylphenidate is a first-line treatment for attention-deficit/hyperactivity disorder (ADHD). In experimental settings, placebo-controlled titration (PCT) of methylphenidate has shown benefits, including the identification of placebo responders and greater symptom improvement. However, the use of PCT in clinical practice remains limited. Implementing PCT may help reduce overprescription of methylphenidate and inform clinical guidelines for the pharmacological management of children with ADHD.